Bristol Myers Squibb @bmsnews · 14 Aug 2026
@bmsnews @US_FDA This getting serious complicated ….. here is the issue big pharma is designing combinatorial drug in a vacuum of the patients immune and genetic status …..May I make a suggestion to medical establishment, FDA included, to have immune / genetic monitoring work up of the patients
44Views
1Likes
0Reposts
0Replies
0Quotes
0Bookmarks
Is that a lot?
0.02×vs this author's median2 188 views is typical
20Percentile for this authorof 10 recent posts
0.01×vs 100K–1M median4 963 views is typical
0.03%Reachviews ÷ followers
2.27%Engagement rateof viewers reacted